Zhongnan Medical Journal Press

Home Results

A total of 7 result was found. Results that relate to Pharmacoeconomics

Pharmacoeconomic evaluation of Huangkui capsule versus losartan potassium tablets in the treatment of IgA nephropathy

Published on Chinese Journal of Pharmacoepidemiology 2023,32(1):02-09.
3304 times 2236 times

Liang-Wen GOU Zhao-Ting GUO Qiong LUO Nan YANG Ming HU

Huangkui capsule Losartan potassium tablets Chronic kidney disease Pharmacoeconomics Cost-utility analysis
Details
Bibliometric analysis of pharmacoeconomics evaluation research in China: based on the Web of Science database

Published on Journal of Mathematical Medicine 2023,36(3):185-193.
1283 times 522 times

Yu-Liang GUI Shi-Qiang XIANG

Pharmacoeconomics evaluation CiteSpace Bibliometrics Visual analysis
Details
Cost-utility analysis of azacitidine versus decitabine in the treatment of myelodysplastic syndrome

Published on Chinese Journal of Pharmacoepidemiology 2023,32(12):1371-1379.
1128 times 455 times

La-Ji DANZENG Yong-Gong YANG Si-Liang WANG Meng-Ying LIU

Azacitidine Decitabine Myelodysplastic syndrome Markov model Cost-utility analysis Pharmacoeconomics
Details
Pharmacoeconomic study of Bailing capsules plus conventional therapy in treating diabetic kidney disease

Published on Chinese Journal of Pharmacoepidemiology 2024,33(3):277-290.
981 times 395 times

HE Yumei LI Wei ZHU He HAN Sheng

Bailing capsules Diabetic kidney disease Meta-analysis Cost- effectiveness analysis Pharmacoeconomics
Details
Partitioned survival model of pharmacoeconomics evaluation of oncology therapy in R language

Published on Journal of Mathematical Medicine 2024,37(4):240-251.
2141 times 598 times

LIU Jiayi LI Wei

R language Pharmacoeconomics evaluation Health economic evaluation Partitioned survival model Oncology treating drugs
Details
Pharmacoeconomic evaluation of glucagon-like peptide-1 receptor agonist combined with metformin in the treatment of type 2 diabetes mellitus

Published on Chinese Journal of Pharmacoepidemiology 2024,33(4):388-401.
1298 times 965 times

YU Tian LIU Shaohua WEI Anhua GUO Jieru ZHANG Chengliang LIU Dong LIU Zhelong

Glucagon-like peptide-1 receptor agonist Metformin Type 2 diabetes mellitus Cost-utility Markov model Pharmacoeconomics
Details
Cost-utiliy comparison of ranibizumab or aflibercept in the treatment of diabetic macular edema based on a Markov model

Published on Frontiers in Pharmaceutical Sciences 2024,27(7):1155-1161.
1175 times 241 times

ZHU Yanxia ZHOU Ruting SHI Tianyan

Diabetic macular edema Aflibercept Ranibizumab Pharmacoeconomics
Details